Chiome Bioscience Inc. (4583.T)
JPY 135.0
(4.65%)
JPY 135.0
(4.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.6 Billion JPY | -0.23% |
| 2022 | 1.6 Billion JPY | -8.5% |
| 2021 | 1.75 Billion JPY | 14.91% |
| 2020 | 1.52 Billion JPY | -9.32% |
| 2019 | 1.68 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 336.74 Million JPY | -11.19% |
| 2024 Q1 | 379.15 Million JPY | -3.12% |
| 2023 Q3 | 344.47 Million JPY | -36.91% |
| 2023 Q2 | 545.99 Million JPY | 69.6% |
| 2023 Q1 | 321.93 Million JPY | -3.38% |
| 2023 FY | 1.6 Billion JPY | -0.23% |
| 2023 Q4 | 391.35 Million JPY | 13.61% |
| 2022 Q3 | 343.97 Million JPY | 0.0% |
| 2022 FY | 1.6 Billion JPY | -8.5% |
| 2022 Q4 | 333.19 Million JPY | -3.13% |
| 2021 FY | 1.75 Billion JPY | 14.91% |
| 2020 FY | 1.52 Billion JPY | -9.32% |
| 2019 FY | 1.68 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -24.858% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -178.038% |
| GNI Group Ltd. | 9.32 Billion JPY | 82.797% |
| Linical Co., Ltd. | 2.7 Billion JPY | 40.715% |
| Trans Genic Inc. | 2.15 Billion JPY | 25.746% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -7.551% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 47.778% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 13.636% |
| AnGes, Inc. | 8.9 Billion JPY | 81.985% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -70.056% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 91.643% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -288.33% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -64.426% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 37.538% |
| CanBas Co., Ltd. | 278 Million JPY | -476.893% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -40.492% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 11.782% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 32.446% |
| PeptiDream Inc. | 9.68 Billion JPY | 83.445% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 18.2% |
| Ribomic Inc. | 1.1 Billion JPY | -45.046% |
| SanBio Company Limited | 4.53 Billion JPY | 64.667% |
| Healios K.K. | 3.48 Billion JPY | 54.007% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -38.885% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -20.18% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -14.272% |
| StemRIM | 2.07 Billion JPY | 22.747% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 18.321% |
| FunPep Company Limited | 313.82 Million JPY | -411.044% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -67.405% |
| Stella Pharma Corporation | 963.98 Million JPY | -66.368% |
| TMS Co., Ltd. | 943.25 Million JPY | -70.025% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -47.141% |
| Cuorips Inc. | 598.11 Million JPY | -168.135% |
| K Pharma,Inc. | 543.94 Million JPY | -194.841% |
| Takara Bio Inc. | 23.9 Billion JPY | 93.291% |
| ReproCELL Incorporated | 1.51 Billion JPY | -5.928% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -35.454% |
| StemCell Institute Inc. | 1.16 Billion JPY | -38.003% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -5.353% |
| CellSeed Inc. | 804.93 Million JPY | -99.242% |